Update shared on21 Sep 2025
Fair value Decreased 20%Despite a notable improvement in net profit margin and a sharply lower future P/E ratio indicating stronger profitability and valuation, the consensus analyst price target for Oncoclínicas do Brasil Serviços Médicos has been revised downward from R$4.49 to R$3.59.
What's in the News
- Special/Extraordinary Shareholders Meetings scheduled for Sep 09, 2025, and Oct 08, 2025, at the company's São Paulo location.
- Oncoclínicas do Brasil Serviços Médicos S.A. removed from the Brazil IBRX Index.
Valuation Changes
Summary of Valuation Changes for Oncoclínicas do Brasil Serviços Médicos
- The Consensus Analyst Price Target has significantly fallen from R$4.49 to R$3.59.
- The Net Profit Margin for Oncoclínicas do Brasil Serviços Médicos has significantly risen from 1.41% to 2.17%.
- The Future P/E for Oncoclínicas do Brasil Serviços Médicos has significantly fallen from 49.48x to 26.15x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.